Cramer's lightning round: 'I am not going to put my money on AstraZeneca'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
More News
AstraZeneca's COPD drug scores two late-stage trial wins
AstraZeneca's COPD drug scores two late-stage trial wins...
CNBC Television-YouTube
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Zacks
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion...
CNBC: Healthcare
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
Zacks
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power
AMD, Costco and AstraZeneca headline Zacks' latest research, with AI demand, membership strength and new drugs shaping their outlooks.
Zacks
Top Stock Reports for AMD, Costco & AstraZeneca
AMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.
Zacks
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.